copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Liquidia Corporation | Corporate Website Liquidia develops innovative therapies for pulmonary hypertension using PRINT® Technology, including YUTREPIA™, an inhalation powder for PAH and PH-ILD
Press releases | Liquidia Corporation MORRISVILLE, N C , Nov 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing
Careers | Liquidia Corporation Explore career opportunities at Liquidia Corporation, a company dedicated to innovation in pulmonary and other diseases
Liquidia Corporation Provides Update on Litigation Filed by United . . . New litigation filed against Liquidia in U S District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA ‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patent Does not impact FDA’s ability to take final action on NDA for YUTREPIA on PDUFA goal date of May
Technology | Liquidia Corporation Enhancing deep-lung delivery of inhaled dry powder Our proprietary PRINT ® technology allows us to produce drug particles of uniform size and shape to potentially improve the safety, efficacy, and performance of a wide range of therapies
Liquidia Corporation to Report Full Year 2022 Financial Results on . . . MORRISVILLE, N C , March 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2022 financial results on Thursday, March 16, 2023 The company will host a webcast at 8:30 a m Eastern Time to discuss financial results and provide a corporate update